Zydus Lifesciences Launches Semaglutide Injection in India
Filing Summary
Zydus Lifesciences Ltd has launched the Semaglutide Injection in India using an innovative reusable multi-dose pen device. The product is available under the brand names SEMAGLYN, MASHEMA, and ALTERME. The Drug Controller General of India has approved the injection for treating Type 2 Diabetes Mellitus and Obesity. The device allows patients to administer different dose strengths from a single pen. The injection will be manufactured at Zydus Biotech Park, Ahmedabad, with an average monthly treatment cost of approximately Rs. 2,200.
Zydus Lifesciences Ltd has introduced the Semaglutide Injection in India, utilizing a reusable multi-dose pen device. The launch occurred on March 21, 2026, and the product will be marketed under the brand names SEMAGLYN, MASHEMA, and ALTERME. The Drug Controller General of India has approved this injection for the treatment of Type 2 Diabetes Mellitus and Obesity.
The reusable pen device is designed to allow patients to select and administer different dose strengths from a single pen. This feature is intended to replace the need for multiple single-dose pens. The injection will be available in a 15mg/3ml cartridge and manufactured at the Zydus Biotech Park in Ahmedabad. The average monthly cost for the treatment is approximately Rs. 2,200.
Diabetes and obesity are significant health challenges in India. According to the International Diabetes Federation, 8.9 crore adults in India are living with diabetes, representing 10.5 percent of the adult population. Obesity rates are also increasing, with a 91 percent rise in prevalence among women and a 146 percent rise among men.
Zydus Lifesciences Ltd is a global lifesciences company focused on discovering, developing, and marketing a broad range of healthcare therapies. The company employs over 29,000 people worldwide, including 1,500 scientists engaged in research and development. Zydus is committed to unlocking new possibilities in lifesciences through quality healthcare solutions.